Site impact on colorectal cancer biological behavior in terms of clinicopathological and molecular features

Journal of B.U.ON.

Volumn 16, Issue 1, 2011, Pages 84-92

  Papagiorgis, Petros C ^a   Zizi, A E ^b   Tseleni, S ^c   Oikonomakis, I N ^d   Sofias, L ^e   Elemenoglou, I S ^b   Patsouris, E ^c   Nikiteas, N I ^c  

^a ATHENS MEDICAL CENTER   (Greece)

^b TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^e Panagia Odigitria General Clinic   (Greece)

Author keywords

Bcl 2; Colorectal tumors; Distal; Ki 67; p53; Proximal

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER STAGING; COLORECTAL CARCINOMA; COMPARATIVE STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79954476347     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Wu X, Chen V, Steele B et al. Subsite- specific incidence rate and stage of disease in colorectal cancer by race, gender, and age group in the United States, 1992-1997. Cancer 2001; 92: 2547-2554.
2. Gonzalez EC, Roetzheim RG, Ferrante JM, Campell R. Predictors of proximal vs. distal colorectal cancers. Dis Colon Rectum 2001; 44: 251-258. (Pubitemid 32173775)
3. Bonithon-Kopp C, Benhamiche AM. Are there several colorectal cancers? Epidemiological data. Eur J Cancer Prev 1999; 8: S3-S12 (Pubitemid 30185691)
4. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990: 6: 759-767.
5. Elnatan J, Coh HS, Smith DR. C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas. Eur J Cancer 1996; 32A: 491-497.
6. De Lattre O, Olschwang S, Law DJ et al. Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 1989; 2: 353-356. (Pubitemid 19189066)
7. Hamelin R, Lauren Puig P, Olschwang S et al. Association of p53 mutations with short survival in CRC. Gastroenterology 1994: 106: 42-48. (Pubitemid 24011863)
8. Breivic J, Lothe RA, Meiling GI, Rognum T, Borresen-Dale AL, Gaudernack G. Different genetic pathways to proximal and distal colorectal cancer, influenced by sex related factors. Int J Cancer 1997; 74: 664-669. (Pubitemid 28037512)
9. Gervaz P, Bouzourene H, Cerottini JP et al. Dukes B colorectal cancer; Distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum 2001; 44: 3: 364-373. (Pubitemid 32226325)
10. Michael-Robinson J, Reid L, Purdie D et al. Proliferation, apoptosis, and survival in high-level microsatellite instability sporadic colorectal cancer. Clin Cancer Res 2001; 7: 2347-2356. (Pubitemid 32751635)
11. Sinicrope F, Hart J, Hsu H-A, Lemoine M, Michelassi F, Stephens LC. Apoptotic and mitotic indices predict survival rates in lymph node negative colon carcinomas. Clin Cancer Res 1999; 5: 1793-1804.
12. Bufil JA. Colorectal cancer; evidence for distinct genetic categories based on proximal or distal tumour location. Ann Intern Med 1990; 113; 779-788.
13. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in CRC. Lancet 2000; 355: 1745-1750. (Pubitemid 30265078)
14. Buglioni S, D'Agnano I, Vasselli S et al. p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically stage II colorectal cancers independent of fluorouracil-based adjuvant therapy. Am J Clin Pathol 2001; 116: 360-368. (Pubitemid 32851969)
15. Mulder J, Baas I, Polak M, Goodman S, Offerhaus G. Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer 1995: 1257-1262.
16. Lenz HJ, Danenberg KD, Leichman CC et al. p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival and site. Clin Cancer Res 1998; 4: 1227-1234. (Pubitemid 28213334)
17. Garrity M, Burgart L, Mahoney M et al. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair and p53 overexpression in patients with Dukes B2 or C colon cancer. J Clin Oncol 2004; 22: 1572-1582. (Pubitemid 41079794)
18. Allegra C, Parr A, Wold L et al. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 2002; 20: 1735-1743. (Pubitemid 34273261)
19. Salminen E, Palmu S, Vahlberg T, Roberts PJ, Soderstrom KO. Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer. World J Castroenterol 2005; 11: 3245-3249. (Pubitemid 40973893)
20. Kyzer S, Gordon P. Determination of proliferative activity in colorectal carcinoma using monoclonal antibody Ki-67. Dis Colon Rectum 1997; 40: 322-325. (Pubitemid 27120141)
21. Jansson A, Sun XF. Ki-67 expression in relation to clinicopathological variables and prognosis in colorectal adenocarcinomas. APMIS 1997; 105: 730-734. (Pubitemid 27417894)
22. Ishida H, Miwa H, Tatsuta M et al. Ki-67 and CEA expression as prognostic markers in Dukes C colorectal cancer. Cancer Letters 2004; 207: 1: 109-115. (Pubitemid 38429893)
23. Hilska M, Collan Y, Laine VJO et al. The significance of tumor markers for proliferation and apoptosis in predicting survival in colorectal cancer. Dis Colon Rectum 2005; 48: 2197-2208. (Pubitemid 43074439)
24. Baretton G, Diebold J, Cristoforis G et al. Apoptosis and immunohistochemical Bcl-2 expression in colorectal adenomas and carcinomas. Cancer 1996; 77: 2: 255-264.
25. Biden K, Simms L, Cummings M et al. Expression of Bcl-2 protein is decreased in colorectal adenocarcinomas with microsatellite instability. Oncogene 1999; 18: 1245-1249. (Pubitemid 29085998)
26. Han SH, Park YM, Hwang TS. Differential expression of Bcl-2, Bcl- XL and p53 in colorectal cancer. J Gastroenterol Hepatol 2006; 21: 1108-1114.
27. Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes B colorectal cancer patients; how much evidence is enough? Ann Oncol 2003; 14: 1026-1038. (Pubitemid 36950166)
28. Nawa T, Kato J, Kawamoto H et al. Differences between right and left-sided colon cancer in patient characteristics, cancer morphology and histology. J Gastroenderol Hepatol 2008; 23: 418-423. (Pubitemid 351342058)
29. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer ofthe proximal colon. Science 1993; 260: 816-819. (Pubitemid 23167612)
30. Hawkins N, Norrie M, Cheong K et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 2002; 122: 1376-1387. (Pubitemid 34465180)
31. Iacopetta B. Are there two sites to colorectal cancer? Int J Cancer 2002; 101: 403-408.
32. Soong R, Powell B, Elsaleh H et al. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma: Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 2000; 36: 2053-2060.
33. Russo A, Bazan V, Iacopetta D, Kerr D, Soussi T, Gebbia N. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005; 23: 7518-7528. (Pubitemid 46291815)
34. Krajewska M, Kim H, Kim C et al. Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers. Clin Cancer Res 2005; 11: 5451-5461. (Pubitemid 41060821)
35. Fernadez-Cebrian J, Nevado Santos M, Vorwald Kubom P et al. Can the clinical outcome in stage II colon carcinomas be predicted by determination of molecular marker expression? Clin Transi Oncol 2007; 9: 663-670.
36. Choi S, Lee K, Bae Y et al. Genetic classification of colorectal cancer based on chromosomal loss and microsatellite instability predicts survival. Clin Cancer Res 2002; 8: 2311-2322. (Pubitemid 34753606)
37. Sugai T, Habano W, Jiao Y-F et al. Analysis of molecular alterations in left- and right- sided colorectal carcinomas reveals distinct pathways of carcinogenesis. J Mol Diagn 2006; 8: 193-201. (Pubitemid 43811242)
38. Papagiorgis P, Oikonomakis I, Karapanagiotou I, Wexner S, Nikiteas N. The impact of tumour location on histopathological expression of colorectal cancer. J BUON 2006; 11: 3: 317-321. (Pubitemid 44756024)
39. Menguid R, Slidell MB, Wolfgang L, Chang DC, Ahuja N. Is there a difference in survival between right- versus left - sided colon cancers? Ann Surg Oncol 2008; 15: 2388-2394.
40. Benedix F, Kube R, Meyer F et al. Comparison of 17,641 patients with right-and left-sided colon cancer: Differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 2010; 53: 57-64.
41. Takeuchi K, Kuwano H, Tsuzuki Y et al. Clinicopathological characteristics of poorly differentiated adenocarcinoma of the colon and rectum. Hepatogastroenterology 2004; 5: 1698-702. (Pubitemid 39389762)